TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change from baseline pain score on Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shoulder Pain and Disability Index (SPADI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation of pancreatic cancer from other pancreatic solid lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hysterectomy rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Anxiety and Depression Symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immune and stromal heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Moderate minutes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: extracellular resistance of the upper back
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the GCA-diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Converted to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of CBD in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete remission rate of AAGN
Endpoint domain: Mortality/survival
Primary endpoint: Partial remission rate of AAGN
Endpoint domain: Mortality/survival
Primary endpoint: Measurement of minerals concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of Potassium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of left ventricular (LV) wall motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in overt tapping accuracy at 1Hz speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in overt tapping accuracy at 4Hz speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in at-home overt tapping accuracy at 1Hz speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in at-home overt tapping accuracy at 4Hz speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants receiving threshold dose
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants willing to participate in YBGT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Measurement of blood pressure changes due to mask use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluation of dyspnea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evaluation of the degree of perceived fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of parathyroid carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Muscle strength under dynamic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Composition BMI (kg/m^2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score variations of Fibromyalgia Impact Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in total SAPS-PD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure risk measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perpendicular Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in facial dyschromia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Postnatal child development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline on the GRID Hamilton Depression Rating Scale (GRID-HAM-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood pressure during hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maintaining ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse reactions related to the ketogenic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Serious Adverse Device Events
Endpoint domain: Adverse events/effects
Primary endpoint: Drug-resistant TB case finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants with AEs Leading to Discontinuation of Study Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Change in liver steatosis degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recorded Speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression of the treated tumor target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in MIND diet score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of dose limiting toxicities in Phase 1a monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events in Phase 1a monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of laboratory abnormalities in Phase 1a monotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Cost of each closure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Geometric Mean Concentration of SARS-CoV-2 S Protein Binding Antibodies 28 Days After First Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration of SARS-CoV-2 S Protein Binding Antibodies 14 Days After Second Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in epivascular glia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Social Responsiveness Scale, Second Edition Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in alcohol specific satiety score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subject self-assessed global aesthetic evolution of the lips
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Perinatal Anxiety Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: No worsening of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Language
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Time to mm ST-segment Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intracranial Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of unknown osteonecrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of children with respiratory infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC0-72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of positive Xpert MTB/RIF Ultra results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incremental costs per additional positive Xpert MTB/RIF Ultra case detected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in kidney oxygenation (cortex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in kidney oxygenation (medulla)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in global kidney perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in kidney inflammation (cortex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in kidney inflammation (medulla)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Concentration (Cmax) of LY3209590
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve from Time Zero to Infinity (AUC[0-inf]) of LY3209590
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of pregnant women reporting Adverse Reactions for 28 days after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of pregnant women reporting Serious Adverse Reactions from the day of vaccination up to 28 days after delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of infants reporting Adverse Reactions from the birthday up to 28 days after birth
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of infants reporting Serious Adverse Reactions from the birthday up to 28 days after birth
Endpoint domain: Adverse events/effects
Primary endpoint: Bishop Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Effectiveness of medical education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Deep Learning model characterization of the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Review of safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Renal damage measured by N-GAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal damage measured by urea/creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of blood samples tested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: end-organ complications post-COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Diabetes Distress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Dual task Interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of medication discrepancies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-procedural TR Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major adverse events at 30 days post procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated vo2 max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in stress hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in inflammatory biomarker of Interleukin 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in inflammatory biomarker of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in skin conductance activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in respiratory sinus arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major CIED infections
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentration of fibrin degradation products (FDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma concentration of D-Dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive functions (executive, memory, attention)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Choking symptom objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain symptom objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in area of chronic wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline in phase iii slope of the volumetric capnograph
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IOP measured using Goldman applanation tonometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in IOP measured using tonopen/Icare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Medications usage as measured by medical record abstraction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Syndecan 1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heparansulfate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events reported associated with tVNS
Endpoint domain: Adverse events/effects
Primary endpoint: Number and intensity of symptoms reported
Endpoint domain: Adverse events/effects
Primary endpoint: Monocular corrected Distance Visual Acuity (CDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular corrected Distance Visual Acuity (CDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular uncorrected intermediate visual acuity (UIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular uncorrected intermediate visual acuity (UIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocular distance corrected intermediate visual acuity (DCIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular distance corrected intermediate visual acuity (DCIVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety and Depression Scale (PHQ-ADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visible ventilation in a two liters breathing bag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep efficacy (%)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Degree of reduction in opiate consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Students' written test achievements
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Risk of death through 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Risk of cardiovascular death through 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Risk of rehospitalization through 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Levels of Gal3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate of intracranial hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: New conduction abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression and Anxiety Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life as measured by FACT questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Apnea-Hypopnea Index at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Epworth Sleepiness Scale Score at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline in SF-36 Questionnaire Score at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes from Baseline in Body composition at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in 6 Minutes Walking Test at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Physical Activity Metric 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Metric 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative VO2-peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypotension occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphological variation in root canal anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of ultrasound images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Rituximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of IL-6 after CPB time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rate and number of cases for adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Biopsy results indicating cancer presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in genetic profile of vaginal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with E-coach
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rhinitis/rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid droplet accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite radiographic progression-free survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical (PSA) progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: postoperative opioid pain medication use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in the Pelvic Floor Distress Inventory-20 (PFDI-20)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Short Form Health Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Patient Global Impression of Improvement (PGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral Health Impact Profile -14
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DMFT Index (Decayed-Missing-Filled-Teeth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periodontal Disease Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alleviation of chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean hourly intraoperative sufentanil requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Serious Adverse Device Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Technical Success using LithoVue Elite System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Parkinson Disease patients treated by domperidone in misuse conditions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accumulation of effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of care actions identified by nurses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Global Cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostics performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delirium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VO2 peak at 2 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assess the anti-tumor activity of APL-5125
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Hidden Blood Loss (HBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lower Extremity Functional Scale (LEFS) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning